FIL Ltd Has $373.67 Million Stake in Insulet Co. (NASDAQ:PODD)

FIL Ltd decreased its position in shares of Insulet Co. (NASDAQ:PODD - Free Report) by 0.7% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,431,307 shares of the medical instruments supplier's stock after selling 9,812 shares during the quarter. FIL Ltd owned about 2.04% of Insulet worth $373,671,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of PODD. SBI Securities Co. Ltd. bought a new position in shares of Insulet during the 4th quarter valued at about $36,000. SRS Capital Advisors Inc. lifted its stake in Insulet by 43.1% in the fourth quarter. SRS Capital Advisors Inc. now owns 186 shares of the medical instruments supplier's stock valued at $49,000 after buying an additional 56 shares in the last quarter. Friedenthal Financial acquired a new position in shares of Insulet in the fourth quarter valued at approximately $57,000. TD Private Client Wealth LLC increased its position in shares of Insulet by 32.6% during the third quarter. TD Private Client Wealth LLC now owns 228 shares of the medical instruments supplier's stock worth $53,000 after acquiring an additional 56 shares in the last quarter. Finally, Assetmark Inc. raised its holdings in shares of Insulet by 1,447.1% during the fourth quarter. Assetmark Inc. now owns 263 shares of the medical instruments supplier's stock worth $69,000 after acquiring an additional 246 shares during the period.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on PODD. Canaccord Genuity Group increased their target price on Insulet from $304.00 to $324.00 and gave the stock a "buy" rating in a report on Friday, February 21st. StockNews.com downgraded Insulet from a "buy" rating to a "hold" rating in a report on Tuesday, March 4th. Citigroup boosted their target price on Insulet from $310.00 to $355.00 and gave the company a "buy" rating in a research note on Friday, February 21st. Raymond James reaffirmed an "outperform" rating and set a $328.00 price target (up from $294.00) on shares of Insulet in a research note on Friday, February 21st. Finally, Stifel Nicolaus boosted their price objective on shares of Insulet from $245.00 to $293.00 and gave the stock a "hold" rating in a research report on Friday, February 21st. Four analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $292.06.

Remove Ads

Insulet Stock Performance

Insulet stock traded up $2.52 during mid-day trading on Friday, hitting $253.99. 596,739 shares of the company's stock traded hands, compared to its average volume of 718,987. Insulet Co. has a fifty-two week low of $160.19 and a fifty-two week high of $289.46. The stock has a market cap of $17.84 billion, a price-to-earnings ratio of 43.87, a P/E/G ratio of 3.62 and a beta of 1.30. The firm has a 50 day simple moving average of $266.67 and a two-hundred day simple moving average of $260.56. The company has a debt-to-equity ratio of 1.21, a current ratio of 3.68 and a quick ratio of 2.80.

Insulet (NASDAQ:PODD - Get Free Report) last announced its quarterly earnings results on Thursday, February 20th. The medical instruments supplier reported $1.15 EPS for the quarter, beating analysts' consensus estimates of $1.00 by $0.15. The business had revenue of $597.50 million for the quarter, compared to analyst estimates of $582.02 million. Insulet had a net margin of 20.19% and a return on equity of 24.46%. On average, research analysts expect that Insulet Co. will post 3.92 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, EVP Eric Benjamin sold 12,394 shares of the firm's stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $280.00, for a total transaction of $3,470,320.00. Following the transaction, the executive vice president now directly owns 11,383 shares of the company's stock, valued at approximately $3,187,240. This trade represents a 52.13 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Wayne A.I. Frederick sold 1,825 shares of the business's stock in a transaction dated Tuesday, March 25th. The shares were sold at an average price of $275.00, for a total transaction of $501,875.00. Following the completion of the sale, the director now directly owns 3,231 shares of the company's stock, valued at $888,525. This represents a 36.10 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 0.47% of the company's stock.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.